It is purely anecdotal, there were two many variables to control for,it was not part of the cancer study protocols.
Dr. Alkon, and his team at BRNI noticed it. It may have been mentioned by Dr. Alkon, at other AD conferences over the years, but I have no knowledge of that.
BRNI would have reviewed those cancer studies perhaps a decade or more ago and while significant to the Bryostatin research team at the time was not supported by any hard data.
News 
Market Data 
Discover 
AI
